Allogene Therapeutics saw the highest growth of 1.99% in patent filings in May and no patents were granted in April in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 0.24% and no change in grants. GlobalData’s DataBook provides a comprehensive analysis of Allogene Therapeutics‘s patent filings and grants. Buy the databook here.
Allogene Therapeutics has been focused on protecting inventions in World Intellectual Property Organization(WIPO) with three publications in Q2 2024
The World Intellectual Property Organization(WIPO) Patent Office dominates the patent filings with nearly 50% of filings. The World Intellectual Property Organization(WIPO), Australia(AU), and European Patent Office(EPO) patent Office are among the top ten patent offices where Allogene Therapeutics is filings its patents..
Immatics and University of Pennsylvania could be the strongest competitors for Allogene Therapeutics
Patents related to cell & gene therapy lead Allogene Therapeutics's portfolio
Allogene Therapeutics has the highest number of patents in cell & gene therapy. For cell & gene therapy, nearly 100% of patents were filed and no patents were granted in Q2 2024.
Cell therapy related patents lead Allogene Therapeutics portfolio
Allogene Therapeutics has highest number of patents in cell therapy.
For comprehensive analysis of Allogene Therapeutics's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.